MS patients on ozanimod: how long does treatment last?
NCT ID NCT05811416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study does not test a new drug—it simply observes real-world use and outcomes over 24 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Barcelona, 08008, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your own blood cells tame MS? early trial shows promise
- Hidden hunger in MS: new study probes link between malnutrition and disability
- Could a gut bacteria byproduct tame MS?
- New MS drug trial aims to reduce brain lesions and relapses
- Could stem cells ease MS symptoms? new trial tests hope
- MS breakthrough? trial tests if older patients can ditch heavy drugs